1. Home
  2. RMTI vs NEUP Comparison

RMTI vs NEUP Comparison

Compare RMTI & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rockwell Medical Inc.

RMTI

Rockwell Medical Inc.

HOLD

Current Price

$0.66

Market Cap

26.7M

Sector

Health Care

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.17

Market Cap

23.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMTI
NEUP
Founded
1994
1996
Country
United States
United States
Employees
300
8
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.7M
23.1M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
RMTI
NEUP
Price
$0.66
$4.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$2.00
$21.00
AVG Volume (30 Days)
316.2K
62.7K
Earning Date
05-07-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$69,258,000.00
N/A
Revenue This Year
$8.64
N/A
Revenue Next Year
$8.44
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.60
$3.65
52 Week High
$2.10
$21.31

Technical Indicators

Market Signals
Indicator
RMTI
NEUP
Relative Strength Index (RSI) 35.53 35.82
Support Level $0.60 $3.91
Resistance Level $1.00 $4.56
Average True Range (ATR) 0.04 0.30
MACD 0.00 -0.06
Stochastic Oscillator 26.60 26.67

Price Performance

Historical Comparison
RMTI
NEUP

About RMTI Rockwell Medical Inc.

Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: